← Leaderboards
Carol A Kruse
University Of Colorado Denver
$3,200,645
Attributed
$5,083,140
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2006–14$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$5,083,140 · 7
By mechanism
R01$4,106,405 · 3
R21$956,875 · 2
M01$19,860 · 2
Top collaborators
- Linda M Liau7 shared
- Boris Minev4 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Jianfu Chen$12,824,478
- Eric Van Otterloo$2,085,596
- Cheryl Lynne Ackert-Bicknell$7,745,724
- Dianna Lynne Bartel$81,198
- Sarah Ashley Martin$132,560
Others in their field
Top investigators on “Brain Neoplasms”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$98,312,615
- Gregory H Reaman · National Childhood Cancer Foundation$78,833,655
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- Robert H Vonderheide · University Of Pennsylvania$60,987,353
Research focus
Brain NeoplasmsGliomaClinical ResearchCytotoxicityCellsTumorNeoplastic CellSurfaceSuccessT-LymphocyteLymphocyteReactionEffector CellAntigensResearch DesignAutologousCytokineAdoptive TransferCytotoxic T-LymphocytesCharacteristicsCytotoxicProductionImmunotherapyResponse
Grant awards (19)
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$14,664
R01 · FY2014 · CA · contact PI
Optimizing Induction Conditions for Immunotherapeutic CTL$370,764
R01 · FY2013 · CA · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$61,181
R01 · FY2013 · CA · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$1
R01 · FY2013 · CA · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$685,920
R01 · FY2012 · CA · contact PI
Optimizing Induction Conditions for Immunotherapeutic CTL$394,429
R01 · FY2012 · CA · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$49,970
R01 · FY2012 · CA · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$690,480
R01 · FY2011 · CA · contact PI
Optimizing Induction Conditions for Immunotherapeutic CTL$394,429
R01 · FY2011 · CA · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$721,946
R01 · FY2010 · CA · contact PI
Optimizing Induction Conditions for Immunotherapeutic CTL$381,207
R01 · FY2010 · CA · contact PI
Proapoptotic Nucleic Acid Agents for Brain Tumor Therapy$238,467
R21 · FY2007 · NS · contact PI
Proapoptotic Nucleic Acid Agents for Brain Tumor Therapy$294,705
R21 · FY2006 · NS · contact PI
ImmunoResistant Brain Tumor Models$246,169
R21 · FY2004 · NS
ImmunoResistant Brain Tumor Models$177,534
R21 · FY2003 · NS
TALL 104 CELLULAR THERAPY FOR PEDIATRIC REFRACTORY PRIMARY BRAIN TUMORS$0
M01 · FY2002 · RR
IMMUNOTHERAPY FOR PRIMARY BRAIN GLIOMA$341,414
R01 · FY2000 · NS
ALLOGENEIC CTL &INTERLEUKIN 2 FOR RECURRENT BRAIN TUMOR$19,860
M01 · FY2000 · RR
TALL 104 CELLULAR THERAPY FOR PEDIATRIC REFRACTORY PRIMARY BRAIN TUMORS$0
M01 · FY2000 · RR